Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) δ-selective agonists

[1]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[2]  P. Renard,et al.  Studies towards the conception of new selective PPARβ/δ ligands , 2006 .

[3]  J. Wityak,et al.  3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists. Part 2. , 2006, Bioorganic & medicinal chemistry letters.

[4]  D. Lang,et al.  Minor structural modifications convert a selective PPARα agonist into a potent, highly selective PPARδ agonist , 2005 .

[5]  D. Kereiakes,et al.  Metabolic syndrome epidemic. , 2003, Circulation.

[6]  H. Miyachi,et al.  Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators. , 2002, Bioorganic & medicinal chemistry letters.

[7]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[8]  Masahiro Suzuki,et al.  Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators. , 2003, Journal of medicinal chemistry.

[9]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Epple,et al.  1,3,5-Trisubstituted aryls as highly selective PPARδ agonists , 2006 .

[11]  Ali H Mokdad,et al.  Increasing prevalence of the metabolic syndrome among u.s. Adults. , 2004, Diabetes care.

[12]  M. Makishima,et al.  Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor α/δ dual agonists , 2006 .

[13]  M. Makishima,et al.  Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. , 2006, Bioorganic & medicinal chemistry.

[14]  H. Miyachi,et al.  Molecular Modeling Study of Species-Selective Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist; Possible Mechanism(s) of Human PPARα Selectivity of an α-Substituted Phenylpropanoic Acid Derivative (KCL) , 2004 .

[15]  W. Wahli,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society Differential Expression of Peroxisome Proliferator- Activated Receptor-�,-�, and- � during Rat , 2022 .

[16]  H. Miyachi,et al.  Analysis of the Critical Structural Determinant(s) of Species-Selective Peroxisome Proliferator-Activated Receptor Alpha (PPARα)-Activation by Phenylpropanoic Acid-Type PPARα Agonists , 2003 .

[17]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[18]  Masahiro Suzuki,et al.  Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. , 2002, Bioorganic & medicinal chemistry letters.

[19]  H. Miyachi,et al.  Efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivative, a selective agonist for human peroxisome proliferator-activated receptor alpha. , 2002, Bioorganic & medicinal chemistry letters.

[20]  R D Cramer,et al.  Three-dimensional structure-activity relationships. , 1988, Trends in pharmacological sciences.

[21]  J. Shaw,et al.  The metabolic syndrome: prevalence in worldwide populations. , 2004, Endocrinology and metabolism clinics of North America.

[22]  Davidr . Evans,et al.  Asymmetric alkylation reactions of chiral imide enolates. A practical approach to the enantioselective synthesis of .alpha.-substituted carboxylic acid derivatives , 1982 .

[23]  J. Gustafsson,et al.  A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma. , 1993, Journal of lipid research.

[24]  Johan Auwerx,et al.  Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.

[26]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.

[27]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[28]  M. Tsunoda,et al.  (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. , 1999, Bioorganic & medicinal chemistry letters.

[29]  D. Noonan,et al.  Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[30]  T. Willson,et al.  Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activity , 2003 .

[31]  V. Skulachev.  Uncoupling: new approaches to an old problem of bioenergetics. , 1998, Biochimica et biophysica acta.

[32]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[33]  Y. Hashimoto,et al.  Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: Dual agonists for human peroxisome proliferator-activated receptor α and δ , 2006 .

[34]  P. Puigserver,et al.  A Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis , 1998, Cell.

[35]  Xie Yongping,et al.  新規PPARδ作動薬としての3,4,5‐三置換イソオキサゾール:1部 , 2006 .

[36]  P. Schrauwen,et al.  Towards comprehension of the physiological role of UCP3. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.